News
INBXV
30.85
0.00%
0.00
Inhibrx Biosciences Advances INBRX-106 Phase 2/3 Trial for Head and Neck Cancer
Reuters · 3d ago
INHIBRX BIOSCIENCES PROVIDES PROGRESS UPDATES ON THE INBRX-106 PROGRAM AND THE EXPANSION COHORTS OF THE OZEKIBART (INBRX-109) PROGRAM
Reuters · 3d ago
Inhibrx Biosciences' Q3 net loss widens, misses EPS estimates
Reuters · 11/14 11:08
Inhibrx Biosciences posts Q3 net loss of $35.3 million
Reuters · 11/14 11:00
INHIBRX REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
Reuters · 11/14 11:00
Inhibrx Biosciences Unveils Positive Phase 2 Results for DR5 Agonist Ozekibart in Chondrosarcoma
Reuters · 11/04 21:02
Transcenta Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma
Reuters · 10/30 22:44
Inhibrx Biosciences Reports Positive Phase 3 Results for Ozekibart in Chondrosarcoma
Reuters · 10/23 20:07
INHIBRX BIOSCIENCES INC - OZEKIBART MEETS PRIMARY ENDPOINT IN CHONDROSARCOMA
Reuters · 10/23 20:05
INHIBRX BIOSCIENCES INC - 23% RESPONSE RATE AND 92% DISEASE CONTROL RATE
Reuters · 10/23 20:05
Inhibrx Biosciences Announces Topline Results from Ozekibart Chondrosarcoma Trial
Reuters · 10/22 20:01
INHIBRX TO HOST WEBCAST PRESENTATION OF TOPLINE RESULTS FROM ITS REGISTRATIONAL TRIAL OF OZEKIBART (INBRX-109) IN CHONDROSARCOMA AND TO PROVIDE UPDATES ON COLORECTAL CANCER AND EWING SARCOMA EXPANSION COHORTS
Reuters · 10/22 20:01
Viking Global Investors LP Reports Disposal of Common Shares in Inhibrx Biosciences Inc
Reuters · 10/09 20:42
Inhibrx Biosciences Reports Q2 2025 Results: Revenue Jumps to $1.3M, Net Loss Hits $28.7M, EPS at -$1.85
Reuters · 08/13 20:06
INHIBRX BIOSCIENCES INC - INBRX-106 PHASE 2 DATA EXPECTED Q4 2025
Reuters · 08/13 20:05
INHIBRX BIOSCIENCES INC - ENTERS EXCLUSIVE LICENSE AGREEMENT WITH NEW COMPANY
Reuters · 04/01 20:05
INHIBRX BIOSCIENCES INC QTRLY SHR LOSS $3.09
Reuters · 03/17 20:05
INHIBRX BIOSCIENCES INC - PHASE 1 TRIAL SHOWS 1 COMPLETE RESPONSE, 3 PARTIAL RESPONSES, 6 STABLE DISEASE CASES
Reuters · 01/21 22:01
INHIBRX BIOSCIENCES ANNOUNCES PRELIMINARY DATA FROM THE PHASE 1 TRIAL OF OZEKIBART (INBRX-109) FOR THE TREATMENT OF COLORECTAL CANCER
Reuters · 01/21 22:01
INHIBRX BIOSCIENCES INC - ENTERS $150 MILLION LOAN AGREEMENT WITH OXFORD FINANCE
Reuters · 01/13 21:15
More
Webull provides a variety of real-time INBXV stock news. You can receive the latest news about Inhibrx Inc through multiple platforms. This information may help you make smarter investment decisions.
About INBXV
Inhibrx, Inc. is a clinical-stage biopharmaceutical company. The Company is a wholly owned subsidiary of Sanofi S.A.